A ‘Pretend’ Growth Stock: Sensata Technologies Holding plc (ST), Assertio Therapeutics, Inc. (ASRT)

Sensata Technologies Holding plc (NYSE:ST) has its shares plummet by -0.5% or $0.27 from its all-time high of $53.9, with ST attaining that price back on November 07, 2019. The drop in the price of the shares saw it stand at $53.63 per share. ST has been trading at a low of $40.78 over the past one year but it surged by 31.51% or $12.85 to reach the $53.63 mark. Following the massive rise in stock price, ST received more attention from investors and analysts. On Thursday, the stock dipped by -0.35%, which caused investors and analysts to worry about it. Following the plunge in price, the ST beta stands at 1.4, implying that its volatility level has gone up by -0.4 ahead of the general market. A look at the stock’s 200-day moving average shows that it is 11.86% above while its 50-day moving average shows that it is currently 8.19% above. Compared to 1.97% average daily volatility of past month, the stock’s average volatility for this week has decreased by -0.02 as the volatility level currently stands at 1.95%.

Over the past seven days, the stock has witnessed a price surge by 4.77%. This massive rise in stock price has caught the attention of both investors and market traders. The stock has performed excellently over the past 52 weeks, rising by 12.6% during that time frame and is now up by 19.6% since this point this year. ST has surged by 14.67% over the past 30 days, with its equity price gaining% of its value over the past ninety days. These figures add up to see the stock record a growth of 9.74% over the past six months.

Market analysts from research firms still remain bullish about the short-term performance of ST. Most of them are of the view that the stock would be able to reach $53.16 over the next 12 months. If that happens, then the stock would witness a -0.88% fall in its price and that would see the stock’s market cap hit an astonishing $9 Billion. Analysts view this stock as a bearish at the moment as its average rating is 2.4. According to Reuters, many of the 11 analysts covering the stock at the moment believe it is a Buy. 7 of them rated ST as a Hold while 3 of them either rated it as a Buy or a Strong Buy. However, 1 of them advised investors to sell the stock if they have it or shouldn’t buy it if they don’t possess any.

The stock’s technical analysis reveals that its 14-day Relative Strength Index (RSI) is currently in a overbought position as it was able to attain 69.3 points. The trading volume now standing at 1174782 shares. The increase of 479732 shares in trading volume shows that traders and investors have shown more interest in the stock over the past few weeks. During that trading session, the average trading volume of ST was 695050 shares, which is more than 1.69 times higher than its usual trading volume.

Assertio Therapeutics, Inc. has seen its stock (NASDAQ:ASRT) surge by $0.02 or 3.43% to currently trade at $0.75. This rise in the price of the stock has seen it establish a strong support at $0.71 a share. If the stock price is to drop below that support level, then it would be followed by a bearish trend. A slip below $0.66 would be bad for ASRT as it would mean that the stock has lost 12% of its value. The stock going in the opposite direction and breaking past the resistance point to reach $0.82 would see it surge even higher. ASRT would attempt to surge past the upward resistance point which is set at $0.88 a share. ASRT has an average volatility of 12.82% over the past 30 days, while it has gained 5.33% of its value compared to its 52-weeks low point which stands at $0.71 on Oct 21, 2019. In the same breath, ASRT has lost 2.67% compared to its 52-weeks high point which currently stands at $0.73 a share reached on Nov 14, 2018.

Analysts have set a 1-year price target for this stock, with most of them expecting it to reach $5.17/share over the next 12 months. If that happens, then ASRT would witness a 589.33% rise from its current price. The price of the stock has been moving between $0.73 and $0.84. Not all analysts believe it would hit that target though, as some of them expect it to trade lower, as low as $3 per share. In the same breath, one analyst believes that the stock is set to soar even higher than expected, as the price target was set at $9.5.

The stock is currently oversold as its Stochastic Oscillator (%D) is at 20.93%, which implies that a jump in price could be experienced soon. Its shares P/S ratio is below the 0.84 industry average and below the 1.02 by the wider market, as ASRT’s P/S ratio currently stands at 0.24. The stock’s estimated price-earnings (P/E) multiple is 0.77 which is also above the 12-month price-earnings (P/E) which stands at 0. Assertio Therapeutics, Inc. has experienced a fall in its earnings, recording an decrease rate of -5.2% in each quarter over the past five years.